Koss Olinger Consulting, LLC Ionis Pharmaceuticals Inc Transaction History

Koss Olinger Consulting, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$43.39 - $51.63 $580,037 - $690,189	-13,368 Reduced 74.65%	4,539 $229,000
Q2 2023 Jul 28, 2023	SELL	$34.73 - $43.33 $12,537 - $15,642	-361 Reduced 1.98%	17,907 $734,000
Q1 2023 May 12, 2023	SELL	$33.58 - $41.2 $9,906 - $12,154	-295 Reduced 1.59%	18,268 $652,000
Q4 2022 Feb 13, 2023	SELL	$37.12 - $46.52 $644,997 - $808,331	-17,376 Reduced 48.35%	18,563 $701,000
Q3 2022 Nov 14, 2022	SELL	$36.54 - $48.66 $108,998 - $145,152	-2,983 Reduced 7.66%	35,939 $1.59 Million
Q2 2022 Jul 08, 2022	SELL	$31.71 - $43.0 $164,828 - $223,514	-5,198 Reduced 11.78%	38,922 $1.44 Million
Q1 2022 May 06, 2022	BUY	$29.88 - $37.04 $446,974 - $554,081	14,959 Added 51.3%	44,120 $1.63 Million
Q4 2021 Feb 07, 2022	BUY	$25.61 - $35.1 $454,039 - $622,287	17,729 Added 155.08%	29,161 $887,000
Q3 2021 Nov 09, 2021	BUY	$33.54 - $40.55 $383,429 - $463,567	11,432 New	11,432 $383,000

402

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $4.64B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Koss Olinger Consulting, LLC, based on Form 13F filings with the SEC.

Stay updated on Koss Olinger Consulting, LLC with notifications on news.